23 December 2025 - South Korea's pharmaceutical and biotech industry has begun mounting a coordinated backlash against the government's plan to slash prices of generic medicines by up to 25% starting next July, warning that the move could sharply erode industry profitability.

Industry groups say the proposed overhaul could result in annual profit losses of as much as 3.6 trillion won ($2.45 billion) — more than three times the figure estimated by the Ministry of Health and Welfare — arguing that the burden would exceed what companies can absorb.

Read Pulse article